** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Now what do I do? Poke an eye out ...
Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to ...
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...
IMR-687 safely increases the levels of fetal hemoglobin and the number of fetal hemoglobin-producing cells in people with sickle cell disease (SCD), according to early data from an ongoing Phase 2a ...
Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes that its portfolio company Imara, Inc. ("Imara") has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback